Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 1/20 | 0.56 |
| ▸ | F10 | P00742 | 3/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.53 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 5/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6114223 | 0.87 | PTGER4 (0.57) | PTGER4 | |
| SCHEMBL8570145 | 0.84 | PTGER4 (0.51) | F10PTGER4ELANE | |
| SCHEMBL27944549 | 0.81 | PTGER4 (0.49) | PTGER4ABHD6ELANE | |
| SCHEMBL27944517 | 0.81 | PTGER4 (0.52) | PTGER4ELANE | |
| SCHEMBL31647277 | 0.80 | PTGER4 (0.60) | PTGER4ELANE | |
| SCHEMBL3775553 | 0.80 | PTGER4 (0.60) | PTGER4ELANE | |
| SCHEMBL1897336 | 0.80 | PTGER4 (0.59) | PTGER4ELANEF2PLAU | |
| SCHEMBL8591344 | 0.78 | PTGER4 (0.52) | PTGER4ELANE | |
| SCHEMBL9941640 | 0.77 | ADORA2A (0.57) | MAPK10F10ABHD6LOXL2TRPA1 | |
| SCHEMBL12884896 | 0.77 | CNR1 (0.65) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120130078-A1 | INDAZOLE DERIVATIVES AS ADENOSINE MONOPHOSPHATE DEAMINASE (AMPD) INHIBITORS FOR USE IN DIABETES AND RELATED DISEASES OF METABOLIC SYNDROME | OCHS RAYMOND S (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120130078-A1 | INDAZOLE DERIVATIVES AS ADENOSINE MONOPHOSPHATE DEAMINASE (AMPD) INHIBITORS FOR USE IN DIABETES AND RELATED DISEASES OF METABOLIC SYNDROME | OCHS RAYMOND S (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130078-A1 | INDAZOLE DERIVATIVES AS ADENOSINE MONOPHOSPHATE DEAMINASE (AMPD) INHIBITORS FOR USE IN DIABETES AND RELATED DISEASES OF METABOLIC SYNDROME | AMPD1, AMPD3, AMPD2 | MAPK10 2305/4885F10 4099/4885PTGER4 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.